Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function
The interstices of the mammalian stratum corneum contain lipids in a system of continuous membrane bilayers critical for the epidermal permeability barrier. During the transition from inner to outer stratum corneum, the content of polar lipids including glucosylceramides, decreases while ceramide co...
Gespeichert in:
Veröffentlicht in: | The Journal of clinical investigation 1993-04, Vol.91 (4), p.1656-1664 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1664 |
---|---|
container_issue | 4 |
container_start_page | 1656 |
container_title | The Journal of clinical investigation |
container_volume | 91 |
creator | HOLLERAN, W. M TAKAGI, Y MENON, G. K LEGLER, G FEINGOLD, K. R ELIAS, P. M |
description | The interstices of the mammalian stratum corneum contain lipids in a system of continuous membrane bilayers critical for the epidermal permeability barrier. During the transition from inner to outer stratum corneum, the content of polar lipids including glucosylceramides, decreases while ceramide content increases. We investigated whether inhibition of glucosylceramide hydrolysis would alter epidermal permeability barrier function. Daily topical applications of bromoconduritol B epoxide (BrCBE) to intact murine skin selectively inhibited beta-glucocerebrosidase, increased glucosylceramide content of stratum corneum with ceramide content remaining largely unchanged, and caused a progressive, reversible decrease in barrier function. Histochemistry of inhibitor-treated epidermis revealed persistence of periodic acid-Schiff-positive staining in stratum corneum cell membranes, consistent with retention of hexose moieties. Electron microscopy of inhibitor-treated samples revealed no evidence of toxicity or changes in the epidermal lipid delivery system. However, immature membrane structures persisted in the intercellular spaces throughout the stratum corneum, with reappearance of mature membrane structures progressing outward from the lower stratum corneum upon termination of BrCBE. Finally, the induced barrier abnormality was not reversed by coapplications of ceramide. These data demonstrate that glucosylceramide hydrolysis is important in the formation of the epidermal permeability barrier, and suggest that accumulation of glucosylceramides in stratum corneum intercellular membrane domains leads to abnormal barrier function. |
doi_str_mv | 10.1172/jci116374 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_288144</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8473508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-877485f858a837dc72cd8f2850a95d8ad6d51d293139eb7808ad0ee1b5f357aa3</originalsourceid><addsrcrecordid>eNpVUMtq3DAUFaUhmSZd9AMCWnSThRs9ozuLLMrQtCmBdpGszbUeUwXbciS7MH8fhRmGdnXgvO7lEPKJsy-cG3H9bCPnN9Kod2TFtYYGhIT3ZMWY4M3aSDgjH0p5ZowrpdUpOQVlpGawIuV3TtaXEsctTYH6KTqfB-zptl9sKrve-oxDJQuNhWb_ssTsHQ0p0zTN8c054FAh4kjtMuPo01LoVEs8drGP8452mHP0mYZltHNM4wU5CdgX__GA5-Tp7tvj5kfz8Ov7_ebrQ2M1U3MDxijQATQgSOOsEdZBEKAZrrUDdDdOcyfWksu17wywSjHveaeD1AZRnpPbfe-0dIN31o9zxr6dcn0779qEsf1fGeOfdpv-tgKgDlXzV_u8zamU7MMxyln7tnv7c3O_3716L_-9dXQehq7654OOxWIfMo42lqNNGaGFYvIVdoWPCw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>HOLLERAN, W. M ; TAKAGI, Y ; MENON, G. K ; LEGLER, G ; FEINGOLD, K. R ; ELIAS, P. M</creator><creatorcontrib>HOLLERAN, W. M ; TAKAGI, Y ; MENON, G. K ; LEGLER, G ; FEINGOLD, K. R ; ELIAS, P. M</creatorcontrib><description>The interstices of the mammalian stratum corneum contain lipids in a system of continuous membrane bilayers critical for the epidermal permeability barrier. During the transition from inner to outer stratum corneum, the content of polar lipids including glucosylceramides, decreases while ceramide content increases. We investigated whether inhibition of glucosylceramide hydrolysis would alter epidermal permeability barrier function. Daily topical applications of bromoconduritol B epoxide (BrCBE) to intact murine skin selectively inhibited beta-glucocerebrosidase, increased glucosylceramide content of stratum corneum with ceramide content remaining largely unchanged, and caused a progressive, reversible decrease in barrier function. Histochemistry of inhibitor-treated epidermis revealed persistence of periodic acid-Schiff-positive staining in stratum corneum cell membranes, consistent with retention of hexose moieties. Electron microscopy of inhibitor-treated samples revealed no evidence of toxicity or changes in the epidermal lipid delivery system. However, immature membrane structures persisted in the intercellular spaces throughout the stratum corneum, with reappearance of mature membrane structures progressing outward from the lower stratum corneum upon termination of BrCBE. Finally, the induced barrier abnormality was not reversed by coapplications of ceramide. These data demonstrate that glucosylceramide hydrolysis is important in the formation of the epidermal permeability barrier, and suggest that accumulation of glucosylceramides in stratum corneum intercellular membrane domains leads to abnormal barrier function.</description><identifier>ISSN: 0021-9738</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/jci116374</identifier><identifier>PMID: 8473508</identifier><identifier>CODEN: JCINAO</identifier><language>eng</language><publisher>Ann Arbor, MI: American Society for Clinical Investigation</publisher><subject>Administration, Topical ; Animals ; Biological and medical sciences ; Cell Membrane Permeability ; Cyclohexenes ; Epidermis - chemistry ; Epidermis - cytology ; Epoxy Compounds - pharmacology ; Fundamental and applied biological sciences. Psychology ; Glucosidases - antagonists & inhibitors ; Glucosylceramides - pharmacokinetics ; Inositol - analogs & derivatives ; Inositol - pharmacology ; Male ; Mice ; Mice, Hairless ; Skin - chemistry ; Skin - cytology ; Sphingolipids - analysis ; Sphingolipids - pharmacokinetics ; Vertebrates: skin, associated glands, phaneres, light organs, various exocrine glands (salt gland, uropygial gland...), adipose tissue, connective tissue</subject><ispartof>The Journal of clinical investigation, 1993-04, Vol.91 (4), p.1656-1664</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-877485f858a837dc72cd8f2850a95d8ad6d51d293139eb7808ad0ee1b5f357aa3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC288144/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC288144/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4725240$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8473508$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HOLLERAN, W. M</creatorcontrib><creatorcontrib>TAKAGI, Y</creatorcontrib><creatorcontrib>MENON, G. K</creatorcontrib><creatorcontrib>LEGLER, G</creatorcontrib><creatorcontrib>FEINGOLD, K. R</creatorcontrib><creatorcontrib>ELIAS, P. M</creatorcontrib><title>Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>The interstices of the mammalian stratum corneum contain lipids in a system of continuous membrane bilayers critical for the epidermal permeability barrier. During the transition from inner to outer stratum corneum, the content of polar lipids including glucosylceramides, decreases while ceramide content increases. We investigated whether inhibition of glucosylceramide hydrolysis would alter epidermal permeability barrier function. Daily topical applications of bromoconduritol B epoxide (BrCBE) to intact murine skin selectively inhibited beta-glucocerebrosidase, increased glucosylceramide content of stratum corneum with ceramide content remaining largely unchanged, and caused a progressive, reversible decrease in barrier function. Histochemistry of inhibitor-treated epidermis revealed persistence of periodic acid-Schiff-positive staining in stratum corneum cell membranes, consistent with retention of hexose moieties. Electron microscopy of inhibitor-treated samples revealed no evidence of toxicity or changes in the epidermal lipid delivery system. However, immature membrane structures persisted in the intercellular spaces throughout the stratum corneum, with reappearance of mature membrane structures progressing outward from the lower stratum corneum upon termination of BrCBE. Finally, the induced barrier abnormality was not reversed by coapplications of ceramide. These data demonstrate that glucosylceramide hydrolysis is important in the formation of the epidermal permeability barrier, and suggest that accumulation of glucosylceramides in stratum corneum intercellular membrane domains leads to abnormal barrier function.</description><subject>Administration, Topical</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cell Membrane Permeability</subject><subject>Cyclohexenes</subject><subject>Epidermis - chemistry</subject><subject>Epidermis - cytology</subject><subject>Epoxy Compounds - pharmacology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glucosidases - antagonists & inhibitors</subject><subject>Glucosylceramides - pharmacokinetics</subject><subject>Inositol - analogs & derivatives</subject><subject>Inositol - pharmacology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Hairless</subject><subject>Skin - chemistry</subject><subject>Skin - cytology</subject><subject>Sphingolipids - analysis</subject><subject>Sphingolipids - pharmacokinetics</subject><subject>Vertebrates: skin, associated glands, phaneres, light organs, various exocrine glands (salt gland, uropygial gland...), adipose tissue, connective tissue</subject><issn>0021-9738</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUMtq3DAUFaUhmSZd9AMCWnSThRs9ozuLLMrQtCmBdpGszbUeUwXbciS7MH8fhRmGdnXgvO7lEPKJsy-cG3H9bCPnN9Kod2TFtYYGhIT3ZMWY4M3aSDgjH0p5ZowrpdUpOQVlpGawIuV3TtaXEsctTYH6KTqfB-zptl9sKrve-oxDJQuNhWb_ssTsHQ0p0zTN8c054FAh4kjtMuPo01LoVEs8drGP8452mHP0mYZltHNM4wU5CdgX__GA5-Tp7tvj5kfz8Ov7_ebrQ2M1U3MDxijQATQgSOOsEdZBEKAZrrUDdDdOcyfWksu17wywSjHveaeD1AZRnpPbfe-0dIN31o9zxr6dcn0779qEsf1fGeOfdpv-tgKgDlXzV_u8zamU7MMxyln7tnv7c3O_3716L_-9dXQehq7654OOxWIfMo42lqNNGaGFYvIVdoWPCw</recordid><startdate>19930401</startdate><enddate>19930401</enddate><creator>HOLLERAN, W. M</creator><creator>TAKAGI, Y</creator><creator>MENON, G. K</creator><creator>LEGLER, G</creator><creator>FEINGOLD, K. R</creator><creator>ELIAS, P. M</creator><general>American Society for Clinical Investigation</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>19930401</creationdate><title>Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function</title><author>HOLLERAN, W. M ; TAKAGI, Y ; MENON, G. K ; LEGLER, G ; FEINGOLD, K. R ; ELIAS, P. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-877485f858a837dc72cd8f2850a95d8ad6d51d293139eb7808ad0ee1b5f357aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Administration, Topical</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cell Membrane Permeability</topic><topic>Cyclohexenes</topic><topic>Epidermis - chemistry</topic><topic>Epidermis - cytology</topic><topic>Epoxy Compounds - pharmacology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glucosidases - antagonists & inhibitors</topic><topic>Glucosylceramides - pharmacokinetics</topic><topic>Inositol - analogs & derivatives</topic><topic>Inositol - pharmacology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Hairless</topic><topic>Skin - chemistry</topic><topic>Skin - cytology</topic><topic>Sphingolipids - analysis</topic><topic>Sphingolipids - pharmacokinetics</topic><topic>Vertebrates: skin, associated glands, phaneres, light organs, various exocrine glands (salt gland, uropygial gland...), adipose tissue, connective tissue</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HOLLERAN, W. M</creatorcontrib><creatorcontrib>TAKAGI, Y</creatorcontrib><creatorcontrib>MENON, G. K</creatorcontrib><creatorcontrib>LEGLER, G</creatorcontrib><creatorcontrib>FEINGOLD, K. R</creatorcontrib><creatorcontrib>ELIAS, P. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HOLLERAN, W. M</au><au>TAKAGI, Y</au><au>MENON, G. K</au><au>LEGLER, G</au><au>FEINGOLD, K. R</au><au>ELIAS, P. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>1993-04-01</date><risdate>1993</risdate><volume>91</volume><issue>4</issue><spage>1656</spage><epage>1664</epage><pages>1656-1664</pages><issn>0021-9738</issn><eissn>1558-8238</eissn><coden>JCINAO</coden><abstract>The interstices of the mammalian stratum corneum contain lipids in a system of continuous membrane bilayers critical for the epidermal permeability barrier. During the transition from inner to outer stratum corneum, the content of polar lipids including glucosylceramides, decreases while ceramide content increases. We investigated whether inhibition of glucosylceramide hydrolysis would alter epidermal permeability barrier function. Daily topical applications of bromoconduritol B epoxide (BrCBE) to intact murine skin selectively inhibited beta-glucocerebrosidase, increased glucosylceramide content of stratum corneum with ceramide content remaining largely unchanged, and caused a progressive, reversible decrease in barrier function. Histochemistry of inhibitor-treated epidermis revealed persistence of periodic acid-Schiff-positive staining in stratum corneum cell membranes, consistent with retention of hexose moieties. Electron microscopy of inhibitor-treated samples revealed no evidence of toxicity or changes in the epidermal lipid delivery system. However, immature membrane structures persisted in the intercellular spaces throughout the stratum corneum, with reappearance of mature membrane structures progressing outward from the lower stratum corneum upon termination of BrCBE. Finally, the induced barrier abnormality was not reversed by coapplications of ceramide. These data demonstrate that glucosylceramide hydrolysis is important in the formation of the epidermal permeability barrier, and suggest that accumulation of glucosylceramides in stratum corneum intercellular membrane domains leads to abnormal barrier function.</abstract><cop>Ann Arbor, MI</cop><pub>American Society for Clinical Investigation</pub><pmid>8473508</pmid><doi>10.1172/jci116374</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9738 |
ispartof | The Journal of clinical investigation, 1993-04, Vol.91 (4), p.1656-1664 |
issn | 0021-9738 1558-8238 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_288144 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
subjects | Administration, Topical Animals Biological and medical sciences Cell Membrane Permeability Cyclohexenes Epidermis - chemistry Epidermis - cytology Epoxy Compounds - pharmacology Fundamental and applied biological sciences. Psychology Glucosidases - antagonists & inhibitors Glucosylceramides - pharmacokinetics Inositol - analogs & derivatives Inositol - pharmacology Male Mice Mice, Hairless Skin - chemistry Skin - cytology Sphingolipids - analysis Sphingolipids - pharmacokinetics Vertebrates: skin, associated glands, phaneres, light organs, various exocrine glands (salt gland, uropygial gland...), adipose tissue, connective tissue |
title | Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T07%3A09%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Processing%20of%20epidermal%20glucosylceramides%20is%20required%20for%20optimal%20mammalian%20cutaneous%20permeability%20barrier%20function&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=HOLLERAN,%20W.%20M&rft.date=1993-04-01&rft.volume=91&rft.issue=4&rft.spage=1656&rft.epage=1664&rft.pages=1656-1664&rft.issn=0021-9738&rft.eissn=1558-8238&rft.coden=JCINAO&rft_id=info:doi/10.1172/jci116374&rft_dat=%3Cpubmed_cross%3E8473508%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8473508&rfr_iscdi=true |